Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases
|| Print ||
|Tuesday, 03 December 2013 10:00 (UTC + 1)|
Dortmund, Germany, December 3, 2013 / B3C newswire / -Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.
Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team.”